PIM1 and neuroblastoma: A novel drug targeting PIM/PI3K/mTOR, AUM302 (IBL-302), has recently been reported in neuroblastoma.84 It has been shown to be very specific, more bioavailable than earlier drugs of the same pipeline and effective in decreasing levels of downstream targets of PIM/PI3K/mTOR, including phosphorylated AKT and N-Myc.